← Leaderboards
Andre Michael Lieber
University Of Washington
$20,253,196
Attributed
$21,625,100
Total exposure
17
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,625,100 · 17
By mechanism
R01$16,971,635 · 7
R21$2,050,080 · 6
P01$1,748,275 · 1
U01$769,500 · 1
P30$81,995 · 1
P41$3,615 · 1
Top collaborators
- Hans-Peter Kiem3 shared
Most similar at University Of Washington
Same institution · by research overlap
- Dmitry Shayakhmetov$15,184,716
- Marjorie Robert-Guroff$2,142,617
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyVectorCellsBaseHematopoietic Stem CellsMediatingGenesIn VivoTransgenesAdenovirusesCd46 AntigenGene TransferGene ExpressionBone MarrowProteinsSafetyTransgene ExpressionIn VitroMalignant NeoplasmsMouse ModelReceptorTumorGeneticVirus
Grant awards (67)
In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure$1,399,750
R01 · FY2025 · AI · contact PI
In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure$658,154
R01 · FY2024 · AI · contact PI
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell Disease$644,784
R01 · FY2024 · HL · contact PI
In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure$685,904
R01 · FY2023 · AI · contact PI
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell Disease$657,943
R01 · FY2023 · HL · contact PI
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell Disease$657,943
R01 · FY2022 · HL · contact PI
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell Disease$657,943
R01 · FY2021 · HL · contact PI
Approach for in vivo gene delivery into hematopoietic stem cells for hemophilia A therapy$592,575
R01 · FY2021 · HL · contact PI
Approach for in vivo gene delivery into hematopoietic stem cells for hemophilia A therapy$592,575
R01 · FY2020 · HL · contact PI
Approach for in vivo gene delivery into hematopoietic stem cells for hemophilia A therapy$630,041
R01 · FY2019 · HL · contact PI
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia$386,250
R01 · FY2019 · HL · contact PI
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia$148,902
R01 · FY2019 · HL · contact PI
Approach for in vivo gene delivery into hematopoietic stem cells for hemophilia A therapy$525,668
R01 · FY2018 · HL · contact PI
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia$386,250
R01 · FY2018 · HL · contact PI
In vivo anti-PD1 gene therapy$168,970
R21 · FY2018 · CA · contact PI
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia$386,250
R01 · FY2017 · HL · contact PI
In vivo anti-PD1 gene therapy$202,112
R21 · FY2017 · CA · contact PI
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia$386,250
R01 · FY2016 · HL · contact PI
Hematopoietic stem cell based gene therapy of breast cancer$168,019
R21 · FY2016 · CA · contact PI
Hematopoietic stem cell based gene therapy of breast cancer$201,623
R21 · FY2015 · CA · contact PI
Evaluation of Vectors based on group B adenoviruses$319,059
R01 · FY2014 · CA · contact PI
Evaluation of Vectors based on group B adenoviruses$855,992
R01 · FY2013 · CA · contact PI
Sten Cell Gene Therapy of Breast Cancer$295,150
R01 · FY2013 · CA · contact PI
Evaluation of Vectors based on group B adenoviruses$386,250
R01 · FY2012 · CA · contact PI
Sten Cell Gene Therapy of Breast Cancer$313,989
R01 · FY2012 · CA · contact PI
Evaluation of Vectors based on group B adenoviruses$313,989
R01 · FY2012 · CA · contact PI
Evaluation of Vectors based on group B adenoviruses$320,779
R01 · FY2011 · CA · contact PI
Sten Cell Gene Therapy of Breast Cancer$313,989
R01 · FY2011 · CA · contact PI
Sten Cell Gene Therapy of Breast Cancer$325,237
R01 · FY2010 · CA · contact PI
Evaluation of Vectors based on group B adenoviruses$323,700
R01 · FY2010 · CA · contact PI
Adenovirus interaction with platelets$195,000
R21 · FY2010 · AI · contact PI
Targeted Transgene Integration through Chromatin tethering for Globin Gene Therap$195,000
R21 · FY2010 · HL · contact PI
Sten Cell Gene Therapy of Breast Cancer$323,700
R01 · FY2009 · CA · contact PI
Evaluation of vectors based on group B adenoviruses$283,054
R01 · FY2009 · HL · contact PI
Adenovirus interaction with platelets$234,000
R21 · FY2009 · AI · contact PI
Targeted Transgene Integration through Chromatin tethering for Globin Gene Therap$234,000
R21 · FY2009 · HL · contact PI
ONCOLYTIC ADENOVIRUSES FOR CERVICAL CANCER GENE THERAPY$226,398
R01 · FY2009 · CA · contact PI
Evaluation of vectors based on group B adenoviruses$283,183
R01 · FY2008 · HL · contact PI
Globin LCR containing Adeno-AAV Vectors$250,400
P01 · FY2008 · HL · contact PI
ONCOLYTIC ADENOVIRUSES FOR CERVICAL CANCER GENE THERAPY$226,398
R01 · FY2008 · CA · contact PI
Globin LCR containing Adeno-AAV Vectors$289,619
P01 · FY2007 · HL · contact PI
Evaluation of vectors based on group B adenoviruses$284,311
R01 · FY2007 · HL · contact PI
ONCOLYTIC ADENOVIRUSES FOR CERVICAL CANCER GENE THERAPY$226,398
R01 · FY2007 · CA · contact PI
Evaluation of vectors based on group B adenoviruses$291,896
R01 · FY2006 · HL · contact PI
Globin LCR containing Adeno-AAV Vectors$277,184
P01 · FY2006 · HL · contact PI
ONCOLYTIC ADENOVIRUSES FOR CERVICAL CANCER GENE THERAPY$233,159
R01 · FY2006 · CA · contact PI
Gene Therapy for HPV-Associated Malignancies$148,037
R21 · FY2006 · CA · contact PI
Evaluation of vectors based on group B adenoviruses$299,045
R01 · FY2005 · HL
Globin LCR containing Adeno-AAV Vectors$269,111
P01 · FY2005 · HL
ONCOLYTIC ADENOVIRUSES FOR CERVICAL CANCER GENE THERAPY$238,770
R01 · FY2005 · CA
Gene Therapy for HPV-Associated Malignancies$151,600
R21 · FY2005 · CA
Globin LCR containing Adeno-AAV Vectors$261,272
P01 · FY2004 · HL
IDENTIFICATION OF NOVEL ADENOVIRUS CELL SURFACE RECEPTORS$3,615
P41 · FY2004 · RR
ONCOLYTIC ADENOVIRUSES--CERVICAL CANCER GENE THERAPY$232,461
R01 · FY2003 · CA
NEW VECTORS FOR GENE THERAPY OF HEMOPHILIA A AND ALPHA-1 ANTITRYPSIN DEFICIENCY$256,500
U01 · FY2002 · HL
ONCOLYTIC ADENOVIRUSES--CERVICAL CANCER GENE THERAPY$225,693
R01 · FY2002 · CA
Deleted adeno AAV vectors for stable gene transfer into hematopoietic stem cells$88,647
P01 · FY2002 · HL
CORE--VECTOR FACILITY$0
P30 · FY2002 · DK
NEW VECTORS FOR GENE THERAPY OF HEMOPHILIA A AND ALPHA-1 ANTITRYPSIN DEFICIENCY$256,500
U01 · FY2001 · HL
ONCOLYTIC ADENOVIRUSES--CERVICAL CANCER GENE THERAPY$219,117
R01 · FY2001 · CA
Deleted adeno AAV vectors for stable gene transfer into hematopoietic stem cells$88,647
P01 · FY2001 · HL
CORE--VECTOR FACILITY$0
P30 · FY2001 · DK
NEW VECTORS FOR GENE THERAPY OF HEMOPHILIA A AND ALPHA-1 ANTITRYPSIN DEFICIENCY$256,500
U01 · FY2000 · HL
Deleted adeno AAV vectors for stable gene transfer into hematopoietic stem cells$223,395
P01 · FY2000 · HL
ONCOLYTIC ADENOVIRUSES--CERVICAL CANCER GENE THERAPY$212,736
R01 · FY2000 · CA
SITE SPECIFIC INTEGRATING ADENO/AAV HYBRID VECTORS$151,719
R21 · FY2000 · DK
CORE--VECTOR FACILITY$81,995
P30 · FY2000 · DK